Leadership moves and fresh guidance at CorMedix

CorMedix (CRMD) is drawing attention after naming CEO Joseph Todisco as Chairman and issuing 2026 revenue guidance of US$300 million to US$320 million, alongside appointing Mike Seckler as EVP & Chief Commercial Officer.

The leadership changes and fresh 2026 revenue guidance arrive after a sharp pullback in CorMedix’s share price. The 7 day share price return shows a decline of 36.50% and the year to date share price return shows a decline of 41.20%. However, the 3 year total shareholder return of 62.50% suggests longer term holders have still seen gains, so recent momentum looks to be fading.

If this kind of healthcare update has your attention, it could be a good moment to look across healthcare stocks for other treatment focused names catching interest.

With CorMedix trading at US$7.15 and some models suggesting the shares sit at a steep intrinsic discount, the key question is whether recent weakness has opened up value or whether the current price already reflects future growth.

Most Popular Narrative: 62.4% Undervalued

With CorMedix last closing at US$7.15 against a widely followed fair value of US$19.00, the narrative frames the current price as a steep discount and anchors that view in revenue expansion, margins and a specific discount rate of 6.956%.

The acquisition of Melinta Therapeutics immediately diversifies and stabilizes CorMedix's revenue base by adding $125–$135 million in expected 2025 revenue from multiple acute care and infectious disease products, which should support top-line growth and enhance earnings visibility.

Integration of Melinta's established hospital commercial infrastructure with CorMedix's assets is expected to unlock $35–$45 million in annual operating expense synergies, improving gross and net margins through increased operational efficiency and economies of scale.

Curious how that acquisition, projected margin lift and the 6.956% discount rate combine to reach US$19.00 per share? The revenue bridge, earnings assumptions and future P/E expectations all sit inside this narrative, and one set of numbers does most of the heavy lifting.

Result: Fair Value of $19 (UNDERVALUED)

However, the story can change quickly if Melinta integration costs eat into those projected synergies or if key trials and label expansions encounter regulatory setbacks.

Build Your Own CorMedix Narrative

If you want to weigh the assumptions yourself and test different scenarios, you can build a version that fits your view in just a few minutes, Do it your way.

A great starting point for your CorMedix research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If CorMedix has sharpened your focus, do not stop here. Broaden your watchlist and give yourself more options when the next opportunity shows up.

• Spot potential value stories early by checking out these 881 undervalued stocks based on cash flows that might be pricing in more pessimism than their cash flows suggest.
• Ride the next wave of automation and data insights by scanning these 26 AI penny stocks that are building real businesses around artificial intelligence.
• Target income-focused opportunities by reviewing these 12 dividend stocks with yields > 3% that combine regular payouts with underlying business fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.